These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34695732)

  • 21. Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?
    Balijepalli P; Sitton CC; Meier KE
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysophosphatidic acid (LPA) and its receptors.
    Noguchi K; Herr D; Mutoh T; Chun J
    Curr Opin Pharmacol; 2009 Feb; 9(1):15-23. PubMed ID: 19119080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lysophosphatidic acid signaling through its receptor initiates profibrotic epithelial cell fibroblast communication mediated by epithelial cell derived connective tissue growth factor.
    Sakai N; Chun J; Duffield JS; Lagares D; Wada T; Luster AD; Tager AM
    Kidney Int; 2017 Mar; 91(3):628-641. PubMed ID: 27927603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipids and eicosanoids in fibrosis: emerging targets for therapy.
    Castelino FV
    Curr Opin Rheumatol; 2012 Nov; 24(6):649-55. PubMed ID: 22810365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
    Tabuchi S
    Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LPA receptors: subtypes and biological actions.
    Choi JW; Herr DR; Noguchi K; Yung YC; Lee CW; Mutoh T; Lin ME; Teo ST; Park KE; Mosley AN; Chun J
    Annu Rev Pharmacol Toxicol; 2010; 50():157-86. PubMed ID: 20055701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.
    Lin ME; Herr DR; Chun J
    Prostaglandins Other Lipid Mediat; 2010 Apr; 91(3-4):130-8. PubMed ID: 20331961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
    Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
    Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand
    Gallezot JD; Nabulsi NB; Holden D; Lin SF; Labaree D; Ropchan J; Najafzadeh S; Donnelly DJ; Cao K; Bonacorsi S; Seiders J; Roppe J; Hayes W; Huang Y; Du S; Carson RE
    J Nucl Med; 2018 Feb; 59(2):327-333. PubMed ID: 28864634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
    Miyabe Y; Miyabe C; Iwai Y; Yokoyama W; Sekine C; Sugimoto K; Harigai M; Miyasaka M; Miyasaka N; Nanki T
    Arthritis Res Ther; 2014 Oct; 16(5):461. PubMed ID: 25273676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lysophosphatidic acid induces erythropoiesis through activating lysophosphatidic acid receptor 3.
    Chiang CL; Chen SS; Lee SJ; Tsao KC; Chu PL; Wen CH; Hwang SM; Yao CL; Lee H
    Stem Cells; 2011 Nov; 29(11):1763-73. PubMed ID: 21915944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promising pharmacological directions in the world of lysophosphatidic Acid signaling.
    Stoddard NC; Chun J
    Biomol Ther (Seoul); 2015 Jan; 23(1):1-11. PubMed ID: 25593637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysophosphatidic acid (LPA) signaling via LPA
    Takahashi K; Fukushima K; Onishi Y; Inui K; Node Y; Fukushima N; Honoki K; Tsujiuchi T
    Biochem Biophys Res Commun; 2017 Jan; 483(1):652-657. PubMed ID: 27993681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases.
    Zhao Y; Hasse S; Zhao C; Bourgoin SG
    Biochem Pharmacol; 2019 Jun; 164():74-81. PubMed ID: 30928673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells.
    Matayoshi S; Chiba S; Lin Y; Arakaki K; Matsumoto H; Nakanishi T; Suzuki M; Kato S
    Int J Oncol; 2013 May; 42(5):1560-8. PubMed ID: 23467751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Edg-Like LPA Receptor-Ligand Interactions.
    Balogh B; Pazmany T; Matyus P
    Curr Pharm Des; 2015; 21(24):3533-47. PubMed ID: 25686617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous lysophosphatidic acid (LPA
    Sattikar A; Dowling MR; Rosethorne EM
    Br J Pharmacol; 2017 Feb; 174(3):227-237. PubMed ID: 27864940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current progress in non-Edg family LPA receptor research.
    Yanagida K; Kurikawa Y; Shimizu T; Ishii S
    Biochim Biophys Acta; 2013 Jan; 1831(1):33-41. PubMed ID: 22902318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
    David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
    PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.